Professor Hao Jihui has successfully developed nano carrier drugs for pancreatic cancer

         According to the "Symposium on the application of gene detection technology in the individualized diagnosis and treatment of tumor" held in Tianjin recently, the research group led by Professor Hao Jihui of the Department of pancreatic cancer, Cancer Hospital of Tianjin Medical University has made a major breakthrough in the field of pancreatic cancer nano carrier drugs: the new multi-layer hybrid nano carrier designed by the research group has realized three effective treatments of layered carrier Ingredients, filling the technical gap in the treatment of pancreatic cancer with nano carriers carrying multiple drugs at the same time, the tumor targeting has been greatly improved, and the toxicity has been reduced while the efficacy has been improved The research results were recently published in the international famous academic journal advanced functional materials, and Professor Hao Jihui was also honored in New York Times Square. Pancreatic cancer is the most malignant cancer in clinic Its 5-year survival rate is less than 5% It can be called "the king of cancer" Because of the hidden early symptoms, only 20% of the patients have the opportunity of surgery when they come to see a doctor Most of the patients can only receive palliative chemotherapy because of distant metastasis and local progress The quality of chemotherapy drugs is directly related to the long-term survival of the patients According to Hao Jihui, a research result published in the international authoritative medical journal New England Journal of British studies in 2011 proposed that folfirinox chemotherapy (5-fluorouracil / calcium folinate combined with oxaliplatin and irinotecan) increased the median survival time of metastatic pancreatic cancer to 11.1 months for the first time (6.8 months in the control group), and the objective response rate increased from 9% to 38% However, in the follow-up clinical practice, it was found that there were serious adverse reactions, such as severe neutropenia, diarrhea, especially about 1 / 3 of the patients who received the program had serious fatigue, affecting their daily life In order to optimize the folfirinox chemotherapy program, Hao Jihui research group and Nie Guangjun, National Center for nanoscience, Chinese Academy of Sciences, designed and synthesized a new multi-layer phospholipid polymer hybrid nano carrier, realized the layered carrier of three effective therapeutic components (5-fluorouracil, oxaliplatin, irinotecan) in folfirinox program, and filled in the carrier of multiple drugs at the same time The technology of nano - carrier for pancreatic cancer treatment is blank This nano carrier can significantly improve the half-life of the drug in vivo circulation, at the same time, it can passively target and enrich in the tumor site, and recognize the integrin receptor highly expressed in pancreatic cancer cells, so that its tumor targeting ability is 10 times higher than that of the control group What's more, its damage to normal tissue is obviously reduced Hao Jihui told reporters that the design of the new nano carrier expanded the application of nanotechnology in the multi drug combination chemotherapy scheme, realized the toxicity reduction and efficiency enhancement of folfirinox scheme, and solved a major problem in the treatment of pancreatic cancer In the next step, they will further study the large-scale synthesis and biological effects of this nano carrier drug, so as to realize its clinical application as soon as possible.